Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 167
1.
Travel Med Infect Dis ; 54: 102608, 2023.
Article En | MEDLINE | ID: mdl-37348666

BACKGROUND: Severe imported P. falciparum malaria is a source of morbi-mortality in non-endemic regions. WHO criteria don't accurately classify patients at risk of complications. There is a need to evaluate new tools such as biomarkers to better identify patients with severe imported malaria. METHODS: A case-control study was conducted in Barcelona, from January 2011-January 2021. Adult patients with microbiologically confirmed P. falciparum malaria were classified according to WHO criteria. Patients with imported non-malarial fevers were included as controls. In each group, angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), soluble triggering receptor expressed on myeloid cells (sTREM-1), C-reactive protein (CRP) and platelets were measured and their concentrations were compared between groups. New groups were made with a modified WHO severity classification and biomarkers' performance was evaluated using multiple imputation models. RESULTS: 131 participants were included: 52 severe malaria, 30 uncomplicated malaria and 49 non-malarial fever cases. All biomarkers except sTREM-1 showed significant differences between groups. Using the modified WHO severity classification, Ang-2 and CRP presented the best AUROC; 0.79 (95%CI 0.64-0.94) and 0.80(95%CI 0.67-0.93). A model combining CRP and Ang-2 showed the best AUROC, of 0.84(95%CI 0.68-0.99), with the highest sensitivity and specificity: 84.6%(95%CI 58.9-98.1) and 77.4% (95%CI 65.9-87.7), respectively. CONCLUSIONS: The combination of Ang-2 and CRP may be a reliable tool for the early identification of severe imported malaria. The use of a rapid prognostic test including the mentioned biomarkers could optimize imported malaria management, with the potential to decrease the rate of complications and hospitalizations in patients with imported malaria.


Malaria, Falciparum , Malaria , Adult , Humans , Case-Control Studies , Malaria, Falciparum/diagnosis , Biomarkers , Prognosis , C-Reactive Protein , Plasmodium falciparum
2.
Travel Med Infect Dis ; 49: 102356, 2022.
Article En | MEDLINE | ID: mdl-35589007

BACKGROUND: Overall, more than 50% of international travelers develop symptoms while traveling and 55% of them seek medical assistance during the trip. We conducted a study to evaluate the usefulness of a Smartphone app called TRIP Doctor® to provide telemedicine to international travelers. METHODS: Participants over 18 years old attending our travel clinic at Hospital Clinic in Barcelona were invited to participate during 2017-2019. After downloading the app, the health status of the traveler was monitored on a daily basis, providing specific medical advice and offering remote contact with specialized physicians through an integrated chat, if needed. RESULTS: From 449 users, 59 (13%) contacted for medical assistance through the app during the trip. Main reasons for telemedicine were diarrhea (25.7%), skin conditions (19.7%) and fever (12.1%). Among patients who contacted, 90% of the travelers did not require to be referred to a local doctor. Symptomatic treatment was the main treatment prescribed (38%). In a 14.7% of the cases a follow-up was not required, a 63.2% recovered and 22.1% were loss of follow-up. After a multivariate analysis, duration of trip >14 days was found to be the only factor associated with the use of telemedicine (OR 2.2, CI 95% 1.1-4.5, p = 0.03). CONCLUSION: In conclusion, travelers using telemedicine travelled for longer periods of time and mostly contacted for mild symptoms which could be solved successfully by remote assistance with our specialized doctors.


Mobile Applications , Physicians , Telemedicine , Adolescent , Humans , Smartphone , Travel
3.
Transpl Infect Dis ; 23(2): e13471, 2021 Apr.
Article En | MEDLINE | ID: mdl-32959494

BACKGROUND: The treatment of tuberculosis (TB) in solid organ transplant (SOT) recipients is challenging owing to interactions between rifampin and immunosuppressive drugs. Rifabutin, a rifamycin with excellent activity against Mycobacterium tuberculosis and that induces cytochrome p450 less, may facilitate treatment. We report our experience with rifabutin for treating TB in SOT recipients and review the available literature. METHODS: A retrospective observational study of all SOT recipients with TB between January 2000 and December 2019. The clinical characteristics and outcomes of patients treated with and without rifabutin-containing regimens were compared and a literature review was conducted. RESULTS: We included 31 SOT recipients with TB, among whom 22 (71%) were men and the median age was 62 years (interquartile range 50-20). There were no significant differences between patients treated with rifabutin (n = 12), rifampin (n = 14), and non-rifamycins (n = 5) in clinical cure rates (83.3%, 64.3%, and 100%, respectively; P = .21), side effects (25%, 37.5%, and 20%, respectively; P = .74), or mortality (16.7%, 35.7%, and 0%, respectively; P = .21). Only one patient, treated with rifampin, suffered graft rejection. The literature review identified 59 SOT recipients with TB treated with rifabutin-containing regimens from 8 publications. Overall, the clinical cure, graft rejection, and mortality rates were 93.2%, 5.1%, and 6.8%, respectively. CONCLUSIONS: Rifabutin-containing regimens offer a reliable alternative to rifampin when treating TB in SOT recipients.


Mycobacterium tuberculosis , Organ Transplantation , Tuberculosis , Female , Humans , Male , Middle Aged , Observational Studies as Topic , Rifabutin , Rifampin , Transplant Recipients
6.
Int J Tuberc Lung Dis ; 24(3): 278-286, 2020 03 01.
Article En | MEDLINE | ID: mdl-32228757

OBJECTIVE: To examine the potential association between vitamin D (VitD) deficiency and latent tuberculosis infection (LTBI) and its effect on TB infection conversion (TBIC) incidence.MATERIAL AND METHODS: We carried out a cross-sectional and prospective cohort study of nine pulmonary TB cases that occurred in 2015-2016 in five nursing homes and one mental disability institution in Castellon, Spain. QuantiFERON®-TB Gold and the tuberculin skin test were used to detect LTBI and TBIC, respectively. Serum 25-hydroxyvitamin D was measured using chemiluminescence immunoassay. Poisson regression and inverse probability weighting were used for statistical analyses.RESULTS: The study included 448 residents, 341 staff members with 48 relatives of TB cases (participation rate 82%): of these, respectively 122 (27.2%), 37 (10.9%) and 7 (14.6%) were LTBI-positive; and respectively 22 (7.7%), 10 (3.8%) and 1 (3.7%) were TBIC-positive. LTBI was not associated with VitD status. Severe VitD deficiency (SVDD; defined as VitD level < 10 ng/ml), found in 45.1% of residents, as well as VitD levels of <30 ng/ml (aRR 10.41 95% CI 1.48-73.26), were associated with increased TBIC risk (adjusted relative risk [aRR] 12.1, 95% CI 1.51-97.10), suggesting SVDD as a threshold effect. CONCLUSION: Severe VitD deficiency is a TBIC risk factor.


Latent Tuberculosis , Cross-Sectional Studies , Humans , Latent Tuberculosis/diagnosis , Latent Tuberculosis/epidemiology , Nursing Homes , Prospective Studies , Spain/epidemiology , Tuberculin Test , Vitamin D
7.
Actas dermo-sifiliogr. (Ed. impr.) ; 111(3): 249-253, abr. 2020. tab, graf
Article Es | IBECS | ID: ibc-191528

ANTECEDENTES: La asociación entre los inhibidores de la dipeptidil peptidasa 4 (iDPP-4) y el penfigoide ampolloso (PA) se ha demostrado en varios estudios. El objetivo principal de este estudio era estimar el uso del tratamiento con iDPP-4i en pacientes diagnosticados de PA en nuestro entorno. MATERIAL Y MÉTODOS: Seleccionamos pacientes diagnosticados histológicamente de PA en nuestro departamento entre octubre de 2015 y octubre de 2018. Realizamos una revisión retrospectiva para evaluar los datos clínicos-epidemiológicos y los patrones de inmunofluorescencia directa (IFD). RESULTADOS: De los 70 pacientes diagnosticados con PA durante el período de estudio, el 50% eran diabéticos y el 88,57% de ellos estaban siendo tratados con un iDPP-4 en el momento del diagnóstico de PA. El iDPP-4 más frecuente era la linagliptina (utilizada en el 18,6% de los pacientes), seguida de la vildagliptina (el 17,1%). La mediana de tiempo de latencia entre el inicio del tratamiento con iDPP-4 y el diagnóstico de PA fue de 27,5 meses, siendo de 16 meses para la linagliptina y 39 meses para la vildagliptina (log Rank < 0,01). La IFD fue negativaUn resultado negativo de DIF fue significativamente más común en pacientes que no fueron tratados con un DPP-4i. El patrón DIF más fuertemente (y significativamente) asociado con el tratamiento con DPP-4i fueron los depósitos lineales de inmunoglobulina G a lo largo de la unión dermoepidérmica. El tratamiento con DPP-4i se retiró en el 87% de los pacientes y el 96% de ellos logró una respuesta completa. CONCLUSIÓN: El tratamiento con DPP-4i es muy común en pacientes con BP en nuestro entorno. El período de latencia entre el inicio del tratamiento y el inicio de la PA parece ser más corto con linagliptina que con otros tipos de gliptinas. Los pacientes que reciben tratamiento con DPP-4i pueden mostrar patrones DIF diferentes a los que no reciben tratamiento


BACKGROUND: The association between dipeptidyl peptidase 4 inhibitors (DPP-4i) and bullous pemphigoid (BP) has been demonstrated in several studies. The main aim of this study was to estimate the use of DPP-4i treatment in patients diagnosed with BP in our setting. METHODS: We selected patients histologically diagnosed with BP in our department between October 2015 and October 2018 and performed a retrospective chart review to assess clinical and epidemiological data and direct immunofluorescence (DIF) patterns. RESULTS: Of the 70 patients diagnosed with BP during the study period, 50% were diabetic and 88.57% of these were being treated with a DPP-4i when diagnosed with BP. The most common DPP-4i was linagliptin (used in 18.6% of patients), followed by vildagliptin (17.1%). The median latency period between initiation of DPP-4i treatment and diagnosis of BP was 27.5 months for all treatments, 16 months for linagliptin, and 39 months for vildagliptin (log rank < 0.01). A negative DIF result was significantly more common in patients not being treated with a DPP-4i. The DIF pattern most strongly (and significantly) associated with DPP-4i treatment was linear immunoglobulin G deposits along the dermal-epidermal junction. DPP-4i treatment was withdrawn in 87% of patients and 96% of these achieved a complete response. CONCLUSIONS: DPP-4i treatment is very common in patients with BP in our setting. The latency period between start of treatment and onset of BP seems to be shorter with linagliptin than with other types of gliptins. Patients receiving DPP-4i treatment may show different DIF patterns to those not receiving treatment


Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Pemphigoid, Bullous/epidemiology , Fluorescent Antibody Technique, Direct/standards , Pemphigoid, Bullous/chemically induced , Retrospective Studies , Dipeptidyl-Peptidase IV Inhibitors/administration & dosage
8.
Actas Dermosifiliogr (Engl Ed) ; 111(3): 249-253, 2020 Apr.
Article En, Es | MEDLINE | ID: mdl-31864538

BACKGROUND: The association between dipeptidyl peptidase 4 inhibitors (DPP-4i) and bullous pemphigoid (BP) has been demonstrated in several studies. The main aim of this study was to estimate the use of DPP-4i treatment in patients diagnosed with BP in our setting. METHODS: We selected patients histologically diagnosed with BP in our department between October 2015 and October 2018 and performed a retrospective chart review to assess clinical and epidemiological data and direct immunofluorescence (DIF) patterns. RESULTS: Of the 70 patients diagnosed with BP during the study period, 50% were diabetic and 88.57% of these were being treated with a DPP-4i when diagnosed with BP. The most common DPP-4i was linagliptin (used in 18.6% of patients), followed by vildagliptin (17.1%). The median latency period between initiation of DPP-4i treatment and diagnosis of BP was 27.5 months for all treatments, 16 months for linagliptin, and 39 months for vildagliptin (log rank < 0.01). A negative DIF result was significantly more common in patients not being treated with a DPP-4i. The DIF pattern most strongly (and significantly) associated with DPP-4i treatment was linear immunoglobulin G deposits along the dermal-epidermal junction. DPP-4i treatment was withdrawn in 87% of patients and 96% of these achieved a complete response. CONCLUSIONS: DPP-4i treatment is very common in patients with BP in our setting. The latency period between start of treatment and onset of BP seems to be shorter with linagliptin than with other types of gliptins. Patients receiving DPP-4i treatment may show different DIF patterns to those not receiving treatment.


Dipeptidyl-Peptidase IV Inhibitors , Pemphigoid, Bullous , Dipeptidyl-Peptidase IV Inhibitors/adverse effects , Humans , Linagliptin/adverse effects , Pemphigoid, Bullous/chemically induced , Retrospective Studies , Vildagliptin
9.
Actas dermo-sifiliogr. (Ed. impr.) ; 110(9): 728-733, nov. 2019. ilus
Article Es | IBECS | ID: ibc-185564

Los hemangiomas infantiles son los tumores benignos más frecuentes en la población pediátrica. Cuando afectan al área lumbar y perineal, algunos casos pueden asociarse a alguna malformación subyacente como una disrafia espinal oculta. El manejo de estos hemangiomas carece de consenso. Describimos 3 casos de niños con hemangiomas lumbosacros y perineales con anomalías en la resonancia magnética y revisamos la literatura para valorar qué pruebas y en qué momento se deben realizar para completar el estudio en estos pacientes. Por lo general, se solicita una ecografía lo más precozmente posible, ya que esta técnica no es posible realizarla una vez que los elementos espinales posteriores se han osificado, lo que generalmente ocurre a los 6 meses de edad. La resonancia magnética es la prueba de referencia para diagnosticar una disrafia espinal oculta. De acuerdo con la literatura, la edad media para este examen debe ser alrededor de los 6 meses, cuando la formación de grasa en el filum terminale se ha visto incrementada. En nuestra opinión, se debería realizar una resonancia magnética a los 6 meses de edad en todos los niños con hemangioma lumbar o perineal, independientemente del tamaño de la lesión, la ausencia de síntomas neurológicos o los resultados de la ecografía


Cutaneous hemangiomas are the most frequent benign tumors in children. When they affect the lumbar and perineal area some cases can be associated with an occult spinal dysraphism. The management of these hemangiomas lack consensus. We report 3 cases of children with lumbosacral and perineal hemangiomas with magnetic resonance image abnormalities and we review the literature to find out the type and timing of tests that should be performed to complete the study in these patients. Ultrasound is typically requested as young as possible, as this imaging technique is not possible 11 the posterior spinal elements have ossified. MRI is the gold standard for diagnosing occult spinal dysraphism. According to the literature, the mean age for MRI screening should be around 6 months, when the fat formation in the filum terminale is expanded. In our opinion, an MRI scan should be performed at 6 months of age in every children with lumbar or perineal hemangioma regardless the lesion size, neurological symptoms or the ultrasound results


Humans , Male , Female , Infant, Newborn , Infant , Hemangioma/diagnostic imaging , Hemangioma/drug therapy , Magnetic Resonance Spectroscopy/methods , Lumbosacral Plexus/diagnostic imaging , Lumbosacral Plexus/pathology , Spinal Dysraphism/diagnostic imaging , Propranolol/administration & dosage , Neurosurgery
10.
Actas dermo-sifiliogr. (Ed. impr.) ; 110(1): 38-42, ene.-feb. 2019. graf, tab, ilus
Article Es | IBECS | ID: ibc-176885

Introducción: La incidencia de uretritis por Haemophilus está aumentando. Nuestro objetivo principal es describir las características clínico-microbiológicas de estos pacientes. Como objetivo secundario discutiremos el tratamiento más adecuado en función de las resistencias antibióticas testadas. Material y métodos: Seleccionamos los pacientes de la Unidad de Infecciones de Transmisión Sexual diagnosticados microbiológicamente de uretritis entre julio de 2015 y julio de 2018. De ellos, seleccionamos aquellos en los que se aisló un Haemophilus mediante cultivo agar chocolate. Las resistencias antibióticas se testaron mediante método de difusión disco-placa. De estos pacientes se recogieron los datos de forma transversal y prospectiva durante las visitas en consultas externas. Resultados: Se aisló un Haemophilus spp. en 33,6% de los pacientes diagnosticados de uretritis. De estos pacientes, la manifestación clínica más frecuente fue la supuración uretral (57,9%) y el 60% eran hombres que tienen sexo con hombres, siendo el aislamiento de este microorganismo más frecuente de forma estadísticamente significativa entre los hombres que tienen sexo con hombres que el aislamiento de Neisseria o Chlamydia. Haemophilus spp. se encontró de forma aislada en el 39,5% de los pacientes, siendo el más frecuente H. parainfluenzae en el 84,2%. El 34,2% de los casos de Haemophilus aislados fueron resistentes a azitromicina y el 26,3% eran resistentes tanto a azitromicina como a tetraciclinas. En los casos en los que no se perdió el seguimiento del paciente (n = 17; 44,7%), el tratamiento administrado de forma empírica consiguió una remisión clínica y microbiológica en 11 pacientes, mientras que en 6 fue necesario administrar una pauta de un nuevo antibiótico. Conclusiones: Haemophilus es un nuevo agente etiológico de uretritis no gonocócicas cuya incidencia está en aumento, especialmente entre hombres que tienen sexo con hombres que practican sexo oral sin protección. Estos pacientes pueden presentar una clínica similar a una uretritis gonocócica. Es necesario confirmar la erradicación debido al elevado número de resistencias antibióticas testadas en Haemophilus spp


Introduction: The incidence of urethritis due to Haemophilus species is increasing. The main aim of this study was to describe the clinical and microbiological characteristics of patients with this form of urethritis. A secondary aim was to discuss the adequacy of treatments in patients with different types of antibiotic resistance. Material and methods: We studied patients with a microbiologically confirmed diagnosis of urethritis seen at the Sexually Transmitted Infections Unit of our hospital between July 2015 and July 2018. We selected all patients in whom Haemophilus species were isolated on chocolate agar. Antibiotic resistance was tested using the disk-diffusion method. Cross-sectional data were collected prospectively during outpatient visits. Results: Haemophilus species were isolated in 33.6% of cases. The most common clinical manifestation was urethral discharge (57.6%); 60% of the patients were men who have sex with men and in this subgroup Haemophilus species were significantly more common than either Neisseria or Chlamydia species. Haemophilus species were found in isolation in 39.5% of patients and the most common one was Haemophilus parainfluenzae (isolated in 84.2% of cases). In total, 34.2% of patients were resistant to azithromycin and 26.3% were resistant to both azithromycin and tetracycline. Empirical treatment achieved clinical and microbiologic cure in 11 of the patients who were not lost to follow-up (n = 17; 44.7%). The remaining 6 patients required treatment with a new antibiotic. Conclusions: Haemophilus species are a new cause of nongonococcal urethritis, whose incidence is rising, particularly in men who have sex with men who engage in unprotected oral sex. The clinical manifestations are similar to those seen in gonococcal urethritis. Eradication of infection must be confirmed due to the high rate of antibiotic resistance associated with Haemophilus species


Humans , Male , Female , Adult , Urethritis/etiology , Haemophilus Infections/complications , Haemophilus/isolation & purification , Anti-Bacterial Agents/therapeutic use , Doxycycline/administration & dosage , Suppuration/diagnosis , Urethritis/diagnosis , Urethritis/microbiology , Cross-Sectional Studies , Prospective Studies , Drug Resistance, Microbial , Ceftriaxone/therapeutic use , Urethra/microbiology , Urethra/pathology
11.
Actas Dermosifiliogr (Engl Ed) ; 110(1): 38-42, 2019.
Article En, Es | MEDLINE | ID: mdl-30390917

INTRODUCTION: The incidence of urethritis due to Haemophilus species is increasing. The main aim of this study was to describe the clinical and microbiological characteristics of patients with this form of urethritis. A secondary aim was to discuss the adequacy of treatments in patients with different types of antibiotic resistance. MATERIAL AND METHODS: We studied patients with a microbiologically confirmed diagnosis of urethritis seen at the Sexually Transmitted Infections Unit of our hospital between July 2015 and July 2018. We selected all patients in whom Haemophilus species were isolated on chocolate agar. Antibiotic resistance was tested using the disk-diffusion method. Cross-sectional data were collected prospectively during outpatient visits. RESULTS: Haemophilus species were isolated in 33.6% of cases. The most common clinical manifestation was urethral discharge (57.6%); 60% of the patients were men who have sex with men and in this subgroup Haemophilus species were significantly more common than either Neisseria or Chlamydia species. Haemophilus species were found in isolation in 39.5% of patients and the most common one was Haemophilus parainfluenzae (isolated in 84.2% of cases). In total, 34.2% of patients were resistant to azithromycin and 26.3% were resistant to both azithromycin and tetracycline. Empirical treatment achieved clinical and microbiologic cure in 11 of the patients who were not lost to follow-up (n=17; 44.7%). The remaining 6 patients required treatment with a new antibiotic. CONCLUSIONS: Haemophilus species are a new cause of nongonococcal urethritis, whose incidence is rising, particularly in men who have sex with men who engage in unprotected oral sex. The clinical manifestations are similar to those seen in gonococcal urethritis. Eradication of infection must be confirmed due to the high rate of antibiotic resistance associated with Haemophilus species.


Exudates and Transudates/microbiology , Haemophilus Infections/diagnosis , Haemophilus/isolation & purification , Urethra/microbiology , Urethritis/microbiology , Acute Disease , Adult , Cross-Sectional Studies , Female , Haemophilus Infections/drug therapy , Humans , Male , Prospective Studies , Urethritis/diagnosis , Urethritis/drug therapy
12.
Actas Dermosifiliogr (Engl Ed) ; 110(9): 728-733, 2019 Nov.
Article En, Es | MEDLINE | ID: mdl-30449349

Cutaneous hemangiomas are the most frequent benign tumors in children. When they affect the lumbar and perineal area some cases can be associated with an occult spinal dysraphism. The management of these hemangiomas lack consensus. We report 3 cases of children with lumbosacral and perineal hemangiomas with magnetic resonance image abnormalities and we review the literature to find out the type and timing of tests that should be performed to complete the study in these patients. Ultrasound is typically requested as young as possible, as this imaging technique is not possible 11the posterior spinal elements have ossified. MRI is the gold standard for diagnosing occult spinal dysraphism. According to the literature, the mean age for MRI screening should be around 6 months, when the fat formation in the filum terminale is expanded. In our opinion, an MRI scan should be performed at 6 months of age in every children with lumbar or perineal hemangioma regardless the lesion size, neurological symptoms or the ultrasound results.


Hemangioma/diagnostic imaging , Skin Neoplasms/diagnostic imaging , Adrenergic beta-Antagonists/therapeutic use , Female , Hemangioma/drug therapy , Humans , Infant , Lipoma/diagnostic imaging , Lumbosacral Region/diagnostic imaging , Male , Perineum/diagnostic imaging , Propranolol/therapeutic use , Skin Neoplasms/drug therapy , Spina Bifida Occulta/diagnostic imaging
13.
Actas Dermosifiliogr (Engl Ed) ; 109(4): 340-345, 2018 May.
Article En, Es | MEDLINE | ID: mdl-29463381

BACKGROUND: The risk of skin cancer in patients treated with narrowband (NB) UV-B phototherapy is not well understood. Although experimental studies have shown that there is a risk, clinical studies have not detected an increased incidence of cancer following treatment. The aim of this study was to determine the incidence of nonmelanoma skin cancer (NMSC) in patients treated with NB UV-B phototherapy at a tertiary care hospital in the Mediterranean area. MATERIAL AND METHODS: We conducted a retrospective chart review of 474 patients who received whole-body NB UV-B phototherapy at our hospital between 2002 and 2016 and identified those diagnosed with NMSC during follow-up. We calculated the corresponding crude and standardized incidence rates and compared these with rates in the general population in a similar geographic area. RESULTS: Of the 474 patients, 193 (40.7%) were men and 281 (59.3%) were women. The mean (SD) follow-up period was 5.8 (3) years. The prevalence of NMSC at the end of the study period was 1.9% and the standardized incidence was 108.3 cases per 100 000 patient-years. The SIR of 1.9 in the study group was not significantly different from that of the general population. The number of patients who needed to be treated with NB UV-B phototherapy for 1 case of NMSC to occur was 1900. CONCLUSION: NB UV-B phototherapy does not appear to be associated with an increased risk of NMSC.


Neoplasms, Radiation-Induced/etiology , Skin Neoplasms/etiology , Ultraviolet Therapy/adverse effects , Adult , Aged , Female , Humans , Incidence , Male , Middle Aged , Neoplasms, Radiation-Induced/epidemiology , Retrospective Studies , Risk , Skin Neoplasms/epidemiology , Spain/epidemiology , Tertiary Care Centers/statistics & numerical data
14.
Actas dermo-sifiliogr. (Ed. impr.) ; 108(6): 571-578, jul.-ago. 2017. ilus, tab, graf
Article Es | IBECS | ID: ibc-164512

Introducción: Los estudios epidemiológicos sobre incidencia de dermatitis alérgica de contacto en población pediátrica son escasos. Algunos trabajos consideran que se trata de una entidad infradiagnosticada, y que en muchos casos no se sospecha clínicamente, no realizándose pruebas epicutáneas. No obstante se han comunicado tasas prevalencia de hasta el 20% de sensibilización a alérgenos en la población pediátrica, por lo que probablemente debería ser tenida en cuenta como una posibilidad diagnóstica en este grupo de edad. Material y método: Se ha realizado un análisis retrospectivo de la base de datos de alergia cutánea del servicio de Dermatología del Hospital General seleccionando los casos diagnosticados en niños de entre 0 y 16 años durante los últimos 15 años (año 2000 hasta 2015). El estudio incluye variables epidemiológicas (edad, sexo, antecedentes de atopia) y clínicas (localización de las lesiones, baterías de alérgenos empleadas, alérgenos positivos y su relevancia). Resultados: De los 4.593 pacientes estudiados con pruebas epicutáneas en los últimos 15 años, 265 (6%) correspondían a niños de 0-16 años. Ciento cuarenta y cuatro pacientes (54,3%) mostraron positividad para al menos uno de los alérgenos parcheados. Los alérgenos más frecuentemente identificados fueron en orden decreciente: tiomersal, cloruro de cobalto, colofonia, parafenilendiamina, dicromato potásico, mercurio y níquel. La sensibilización fue considerada de relevancia presente en 177 casos (61,3%). Conclusión: Más de la mitad de los niños estudiados mostraron sensibilización a uno o más alérgenos, con un porcentaje importante de sensibilizaciones relevantes. Todo niño con sospecha clínica de dermatitis alérgica de contacto debería ser remitido para realización de pruebas epicutáneas. Al no existir pruebas estandarizadas en este colectivo se requiere un alto nivel de sospecha clínica y un conocimiento de los alérgenos más frecuentemente implicados de cara a seleccionar los alérgenos a parchar (AU)


Background: Few epidemiological studies have investigated the incidence of allergic contact dermatitis in children. Underdiagnosis has been observed in some studies, with many cases in which the condition is not suspected clinically and patch tests are not performed. However, the prevalence of pediatric sensitization to allergens has been reported to be as high as 20%, and the diagnosis should therefore be contemplated as a possibility in this age group. Material and methods: We performed a retrospective analysis of the skin allergy database of the Dermatology Department of Consorcio Hospital General Universitario de Valencia. Children between 0 and 16 years of age diagnosed with allergic contact dermatitis in the previous 15 years (between 2000 and 2015) were included in the analysis. Epidemiological (age, sex, history of atopy) and clinical (site of the lesions, allergen series applied, positive reactions, and their relevance) variables were gathered. Results: Patch tests had been performed on 4,593 patients during the study period. Of these, 265 (6%) were children aged between 0 and 16 years. A positive reaction to at least one of the allergens tested was observed in 144 (54.3%) patients in that group. The allergens most frequently identified were the following (in decreasing order of frequency): thiomersal, cobalt chloride, colophony, paraphenylenediamine, potassium dichromate, mercury, and nickel. The sensitization was considered relevant in 177 (61.3%) cases. Conclusions: More than half of the children studied showed sensitization to 1 or more allergens, with a high percentage of relevant sensitizations. All children with a clinical suspicion of allergic contact dermatitis should be referred for patch testing. As no standardized test series have been developed for this age group, a high level of clinical suspicion and knowledge of the allergens most commonly involved are required when selecting the allergens to be tested (AU)


Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Dermatitis, Allergic Contact/epidemiology , Dermatitis, Atopic/epidemiology , Patch Tests , Skin Tests , Allergens/analysis , Hypersensitivity/classification
15.
Actas dermo-sifiliogr. (Ed. impr.) ; 108(5): 400-406, jun. 2017. ilus, graf
Article Es | IBECS | ID: ibc-163782

La enfermedad xantogranulomatosa orbitaria del adulto comprende un grupo heterogéneo de síndromes clínicos con diferentes grados de afectación sistémica y pronóstico variable. Todas las formas se manifiestan clínicamente como lesiones amarillentas infiltradas orbitarias de crecimiento progresivo. Histológicamente se caracteriza por un infiltrado inflamatorio compuesto fundamentalmente por histiocitos espumosos y células gigantes multinucleadas tipo Touton. Estos histiocitos xantomatizados son CD68+, S100- y CD1a-. Existen 4 formas clínicas de enfermedad xantogranulomatosa orbitaria del adulto: el xantogranuloma orbitario del adulto, el asma del adulto asociado a xantogranulomas orbitarios, el xantogranuloma necrobiótico y la enfermedad de Erdheim-Chester. El tratamiento de las lesiones locales se basa fundamentalmente en corticosteroides sistémicos y otros inmunosupresores. En los casos con enfermedad sistémica vemurafenib, tocilizumab y sirolimus ofrecen resultados prometedores (AU)


Adult xanthogranulomatous disease of the orbit refers to a heterogeneous group of clinical syndromes with differing degrees of systemic involvement and distinct prognoses. The different syndromes all present clinically with progressively enlarging, yellowish lesions of the orbit. Histologically, the lesions are characterized by an inflammatory infiltrate of foam cells and Touton-type multinucleated giant cells. The xanthomatized histiocytes are CD68+, S100-, and CD1a-. There are 4 clinical forms of xanthogranulomatous disease of the orbit: adult xanthogranulomatous disease of the orbit, adult onset asthma and periocular xanthogranuloma, necrobiotic xanthogranuloma, and Erdheim-Chester disease. The treatment of local lesions are treated with systemic corticosteroids and other immunosuppressors. Vemurafenib, tocilizumab, and sirolimus have shown promising results in systemic disease (AU)


Humans , Necrobiotic Xanthogranuloma/diagnosis , Orbital Diseases/diagnosis , Erdheim-Chester Disease/diagnosis , Adrenal Cortex Hormones/therapeutic use , Histiocytosis, Langerhans-Cell/diagnosis , Giant Cells/pathology
16.
Actas Dermosifiliogr ; 108(5): 400-406, 2017 Jun.
Article En, Es | MEDLINE | ID: mdl-28262109

Adult xanthogranulomatous disease of the orbit refers to a heterogeneous group of clinical syndromes with differing degrees of systemic involvement and distinct prognoses. The different syndromes all present clinically with progressively enlarging, yellowish lesions of the orbit. Histologically, the lesions are characterized by an inflammatory infiltrate of foam cells and Touton-type multinucleated giant cells. The xanthomatized histiocytes are CD68+, S100-, and CD1a-. There are 4 clinical forms of xanthogranulomatous disease of the orbit: adult xanthogranulomatous disease of the orbit, adult onset asthma and periocular xanthogranuloma, necrobiotic xanthogranuloma, and Erdheim-Chester disease. The treatment of local lesions are treated with systemic corticosteroids and other immunosuppressors. Vemurafenib, tocilizumab, and sirolimus have shown promising results in systemic disease.


Histiocytosis/pathology , Orbital Diseases/pathology , Adrenal Cortex Hormones/therapeutic use , Adult , Antibodies, Monoclonal/therapeutic use , Combined Modality Therapy , Diagnosis, Differential , Disease Management , Erdheim-Chester Disease/diagnosis , Erdheim-Chester Disease/pathology , Erdheim-Chester Disease/therapy , Histiocytosis/diagnosis , Histiocytosis/therapy , Humans , Immunosuppressive Agents/therapeutic use , Necrobiotic Xanthogranuloma/diagnosis , Necrobiotic Xanthogranuloma/pathology , Necrobiotic Xanthogranuloma/therapy , Orbital Diseases/diagnosis , Orbital Diseases/therapy , Radiotherapy, Adjuvant
17.
Actas Dermosifiliogr ; 108(6): 571-578, 2017.
Article En, Es | MEDLINE | ID: mdl-28284423

BACKGROUND: Few epidemiological studies have investigated the incidence of allergic contact dermatitis in children. Underdiagnosis has been observed in some studies, with many cases in which the condition is not suspected clinically and patch tests are not performed. However, the prevalence of pediatric sensitization to allergens has been reported to be as high as 20%, and the diagnosis should therefore be contemplated as a possibility in this age group. MATERIAL AND METHODS: We performed a retrospective analysis of the skin allergy database of the Dermatology Department of Consorcio Hospital General Universitario de Valencia. Children between 0 and 16 years of age diagnosed with allergic contact dermatitis in the previous 15 years (between 2000 and 2015) were included in the analysis. Epidemiological (age, sex, history of atopy) and clinical (site of the lesions, allergen series applied, positive reactions, and their relevance) variables were gathered. RESULTS: Patch tests had been performed on 4,593 patients during the study period. Of these, 265 (6%) were children aged between 0 and 16 years. A positive reaction to at least one of the allergens tested was observed in 144 (54.3%) patients in that group. The allergens most frequently identified were the following (in decreasing order of frequency): thiomersal, cobalt chloride, colophony, paraphenylenediamine, potassium dichromate, mercury, and nickel. The sensitization was considered relevant in 177 (61.3%) cases. CONCLUSIONS: More than half of the children studied showed sensitization to 1 or more allergens, with a high percentage of relevant sensitizations. All children with a clinical suspicion of allergic contact dermatitis should be referred for patch testing. As no standardized test series have been developed for this age group, a high level of clinical suspicion and knowledge of the allergens most commonly involved are required when selecting the allergens to be tested.


Dermatitis, Allergic Contact/epidemiology , Tertiary Care Centers , Adolescent , Allergens/adverse effects , Child , Child, Preschool , Databases, Factual , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/etiology , Drug Hypersensitivity/epidemiology , Female , Humans , Hypersensitivity, Immediate/epidemiology , Infant , Infant, Newborn , Male , Patch Tests , Prevalence , Retrospective Studies , Spain/epidemiology , Tertiary Care Centers/statistics & numerical data
18.
Rev Esp Quimioter ; 29(3): 123-9, 2016 Jun.
Article Es | MEDLINE | ID: mdl-27062981

OBJECTIVE: At present there is a controversy regarding the impact of positive bile cultures on morbidity and mortality rates, and on the incidence of readmissions in patients with biliar disease. The aim of this study was to evaluate the role of bacteriobilia in postoperatory infections, mortality or readmissions in these patients. METHODS: The information was obtained from all patients with bile cultures admitted to Hospital Universitario Marqués de Valdecilla (Santander, Spain) from January to December 2011. Clinical, epidemiological and microbiological data and laboratory findings were analyzed. The patients were followed for two years. RESULTS: One hundred and fifty-two patients (65% men) were included. Mean age was 67 years (SD= 15 years). The most frequent diagnoses were acute cholecystitis (79%) and cholangitis (8%). Laparoscopic cholecystectomy was performed in 42% of patients, open cholecystectomy in 45% and percutaneous cholecystostomy in 8%. Bacteriobilia was present in 83 patients (55%). The most frecuent microorganisms isolated were Escherichia coli (31%), Enterococcus faecium (13%) and Klebsiella pneumoniae (13%). The initial antimicrobial agent was a carbapenem in 62 patients (44%) and piperacillin-tazobactam in 28 (18%). There were 39 postoperative infections (26%), 21 readmissions (14%) and 17 patients died during admission (11%). The presence of microorganisms in bile cultures was not a statistically significant predictor of neither complications nor readmissions. CONCLUSIONS: Intra-operative bile cultures would allow guide early appropriate antibiotic treatment use in case of infection, or empiric antimicrobial therapy, however there was no correlation between bacteriobilia and postoperative infections, length of stay, mortality or readmissions.


Bacterial Infections/microbiology , Bile Duct Diseases/microbiology , Postoperative Complications/microbiology , Adult , Age Factors , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/complications , Bacterial Infections/mortality , Bile/microbiology , Bile Duct Diseases/complications , Bile Duct Diseases/mortality , Cholangitis/surgery , Cholecystectomy , Cholecystectomy, Laparoscopic , Cholecystitis/surgery , Cholecystostomy , Female , Humans , Male , Middle Aged , Patient Readmission/statistics & numerical data , Postoperative Complications/mortality , Prognosis
19.
Epidemiol Infect ; 143(8): 1731-41, 2015 Jun.
Article En | MEDLINE | ID: mdl-25274036

The objective of this study was to estimate the relationship between serum vitamin D (VitD) status and tuberculosis (TB) infection conversion (TBIC), measured by the tuberculin skin test (TST) and an interferon-gamma release assay, the QuantiFERON-TB Gold In-Tube (QFT-GIT) test, in the contacts of pulmonary TB patients in Castellon (Spain) in a prospective cohort study from 2010 to 2012. Initially, the participants were negative to latent TB infection after a screening that included TST and QFT-GIT tests, and other examinations. A baseline determination of 25-hydroxyvitamin D [25(OH)D] was obtained by chemiluminescence immunoassay. After 8-10 weeks, participants were screened for a second time to determine TB infection conversion (TBIC). Poisson regression models were used in the statistical analysis. Of the 247 participants in the cohort, 198 (80·2%) were screened twice and 18 (9·1%) were TBIC cases. The means of VitD concentration in the TBIC cases and the non-cases were 20·7±11·9 and 27·2±11·4 ng/ml (P = 0·028), respectively. Adjusted for high exposure and TB sputum acid-fast bacilli (AFB)-positive index case, higher serum VitD concentration was associated with low incidence of TBIC (P trend = 0·005), and an increase of 1 ng/ml VitD concentration decreased the incidence of TBIC by 6% (relative risk 0·94, 95% confidence interval 0·90-0·99, P = 0·015). The results suggest that sufficient VitD level could be a protective factor of TBIC.


Latent Tuberculosis/transmission , Tuberculosis, Pulmonary/transmission , Vitamin D Deficiency/epidemiology , Vitamin D/analogs & derivatives , Adult , Cohort Studies , Female , Humans , Interferon-gamma Release Tests , Latent Tuberculosis/epidemiology , Latent Tuberculosis/immunology , Male , Middle Aged , Poisson Distribution , Prospective Studies , Regression Analysis , Risk Factors , Tuberculin Test , Tuberculosis/epidemiology , Tuberculosis/immunology , Tuberculosis/transmission , Tuberculosis, Pulmonary/epidemiology , Tuberculosis, Pulmonary/immunology , Vitamin D/blood , Vitamin D Deficiency/blood
20.
Int J Tuberc Lung Dis ; 19(1): 65-9, 2015 Jan.
Article En | MEDLINE | ID: mdl-25519792

A prospective cohort study was conducted from 2009 to 2012 to assess the relationship between serum baseline 25-hydroxivytamin D (vitamin D) status and the incidence of tuberculosis (TB) among 572 contacts of 89 pulmonary TB patients in Castellon, Spain. Three new cases of pulmonary TB occurred, with an incidence density of 3.6 per 1000 person-years. Mean vitamin D status was 13.7 ng/ml for cases and 25.7 ng/ml for non-cases. Vitamin D status showed a significant inverse association with TB incidence (adjusted HR 0.88, 95%CI 0.80-0.97). This result is in line with the hypothesis that vitamin D deficiency is associated with TB incidence.


Tuberculosis, Pulmonary/blood , Tuberculosis, Pulmonary/epidemiology , Vitamin D Deficiency/blood , Vitamin D/blood , Adult , Female , Humans , Incidence , Male , Middle Aged , Proportional Hazards Models , Prospective Studies , Risk Factors , Spain , Tuberculosis, Pulmonary/complications , Vitamin D Deficiency/complications , Young Adult
...